HC Wainwright & Co. Reiterates Buy on Fortress Biotech, Maintains $24 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Joseph Pantginis has reiterated a Buy rating on Fortress Biotech (NASDAQ:FBIO) and maintained a $24 price target.
July 19, 2024 | 5:49 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Joseph Pantginis has reiterated a Buy rating on Fortress Biotech (NASDAQ:FBIO) and maintained a $24 price target.
The reiteration of a Buy rating and the maintenance of a $24 price target by a reputable analyst can boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100